The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
Open accessAbstract
BACKGROUND: Decisions about systemic treatment of women with metastatic breast cancer are often based on estrogen receptor (ER), progesterone receptor (PgR), and Her2 status of the primary tumor. This study prospectively investigated concordance in receptor status between primary tumor and distant metastases and assessed the impact of any discordance on patient management. MATERIALS AND METHODS: Biopsies of suspected metastatic lesions were obtained from patients and analyzed for ER/PgR and Her2. Receptor status was compared for metastases and primary tumors. Questionnaires were completed by the oncologist before and after biopsy to determine whether the biopsy results changed the treatment plan. RESULTS: Forty women were enrolled; 35 of them underwent biopsy, yielding 29 samples sufficient for analysis; 3/29 biopsies (10%) showed benign disease. Changes in hormone receptor status were observed in 40% (P = 0.003) and in Her2 status in 8% of women. Biopsy results led to a change of management in 20% of patients (P = 0.002). CONCLUSIONS: This prospective study demonstrates the presence of substantial discordance in receptor status between primary tumor and metastases, which led to altered management in 20% of cases. Tissue confirmation should be considered in patients with clinical or radiological suspicion of metastatic recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Gutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.172 · Cited by 489
Kuukasjärvi, T., Kononen, J., Helin, H., Holli, K., & Isola, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2584 · Cited by 358
Rhodes, A., Jasani, B., Barnes, D. M., Bobrow, L. G., & Miller, K. D. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.2.125 · Cited by 325
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M. J., Ebbs, S. R., & Dowsett, M. (1995) · PubMed · Cited by 301
Multiple estrogen receptor assays in human breast cancer.
Hull, D. F., Clark, G. M., Osborne, C. K., Chamness, G. C., Knight, W. A., & McGuire, W. L. (1983) · PubMed · Cited by 174
Broom, R. J., Tang, P. A., Simmons, C. E., Bordeleau, L. J., Mulligan, A. M., O’Malley, F. P., Miller, N. A., Andrulis, I. L., Brenner, D. M., & Clemons, M. J. (2009) · PubMed · Cited by 152
Self-citationChange of HER‐2/neu status in a subset of distant metastases from breast carcinomas
Regitnig, P., Schippinger, W., Lindbauer, M., Samonigg, H., & Lax, S. (2004) · The Journal of Pathology · doi:10.1002/path.1592 · Cited by 129
Agulnik, M., Oza, A. M., Pond, G. R., & Siu, L. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4496 · Cited by 99
Lipton, A., Leitzel, K., Ali, S. M., et al. (2005) · Cancer · doi:10.1002/cncr.21202 · Cited by 98
Cited by
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju066 · Cited by 615
“phenomenon and may lead to treatment changes in up to 20% of patients (40,41).”
BackgroundLindström, L. S., Karlsson, E., Wilking, U. M., Johansson, U., Hartman, J., Lidbrink, E. K., Hatschek, T., Skoog, L., & Bergh, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2482 · Cited by 523
Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., Oldfield, M., Dranitsaris, G., Tomlinson, G., Laupacis, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5232 · Cited by 434
“These findings are similar to those published previously.(7,8,20,21) No baseline factors were identified that increased the likelihood of change in therapy, although triple-negative tumors tended not to be discordant.”
Self-citationNiikura, N., Liu, J., Hayashi, N., Mittendorf, E. A., Gong, Y., Palla, S. L., Tokuda, Y., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Ueno, N. T. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8889 · Cited by 410
Van Poznak, C., Somerfield, M. R., Bast, R. C., Cristofanilli, M., Goetz, M. P., Gonzalez-Angulo, A. M., Hicks, D. G., Hill, E. G., Liu, M. C., Lucas, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1459 · Cited by 404
Metadata
- Authors
- Simmons, C., Miller, N., Geddie, W., Gianfelice, D., Oldfield, M., Dranitsaris, G., & Clemons, M. J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 20
- Issue
- 9
- Pages
- 1499-1504
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2119065193
- Cited by
- 286
- References
- 13
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? https://app.cochat.ai/papers/10.1093/annonc/mdp028
- The paper
- Simmons, C., Miller, N., Geddie, W., Gianfelice, D., Oldfield, M., Dranitsaris, G., & Clemons, M. J. (2009). Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Annals of Oncology. https://doi.org/10.1093/annonc/mdp028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.